Regular ArticleSurvival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian Cancer☆,☆☆
References (29)
- et al.
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study
Gynecol Oncol
(1992) - et al.
Stage III epithelial ovarian cancer: the role of maximal surgical reduction
Gynecol Oncol
(1984) - et al.
Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment
Gynecol Oncol
(1994) - et al.
Neoadjuvant chemotherapy for advanced ovarian cancer
Gynecol Oncol
(1994) - et al.
Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma
Clin Oncol (Royal College of Radiologists
(1993) - et al.
Effect of surgical debulking on survival in Stage IV ovarian cancer
Gynecol Oncol
(1997) - et al.
Stage IV ovarian cancer: Impact of surgical debulking
Gynecol Oncol
(1997) - et al.
Prognostic significance of residual disease in patients with Stage IV epithelial ovarian cancer
Gynecol Oncol
(1997) - et al.
The role of cytoreductive surgery in the management of Stage IV epithelial ovarian carcinoma
Gynecol Oncol
(1992) Controversial aspects of cytoreductive surgery in epithelial ovarian cancer
Bailliere's Clin Obstet Gynecol
(1989)
The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer
Bailliere's Clin Obstet Gynecol
(1989)
Cancer statistics 1997
CA Cancer J Clin
(1997)
Tumors of the Female Pelvic Organs
(1935)
Cited by (297)
Epithelial ovarian cancer
2023, DiSaia and Creasman Clinical Gynecologic OncologyResponse to treatment and prognostic significance of supradiaphragmatic disease in patients with high-grade serous ovarian cancer
2022, European Journal of Surgical OncologySurgical Management of Gynecologic Cancers
2021, Surgical Oncology Clinics of North AmericaCitation Excerpt :The bulk of evidence supporting hepatic resection in gynecologic malignancies comes from studies on ovarian cancer. In the setting of primary cytoreductive surgery, a number of retrospective studies are discussed, reporting impressive survival outcomes (exceeding 50 months OS) among ovarian cancer patients treated with hepatic resection.10,36 These studies are limited in sample size and of course one must strongly consider selection bias given their retrospective nature.
- ☆
Presented at the 29th Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, February 7–11, 1998.
- ☆☆
Pettersson, F
Copyright © 1999 Academic Press. All rights reserved.